AG真人官方

Form 4 filing reveals that Anthony Gregg Lapointe, Director of Soligenix, received a stock option grant on June 20, 2025. The derivative securities transaction details include:

• Granted 17,647 stock options to purchase common stock
• Exercise price set at $1.70 per share
• Options expire on June 20, 2035
• Vesting schedule occurs in four equal installments: - September 20, 2025 - December 20, 2025 - March 20, 2026 - June 20, 2026

This grant represents standard director compensation and indicates continued board engagement. The 10-year option term provides long-term alignment with shareholder interests.

Form 4 Filing Details: Jerome B. Zeldis, Director of Soligenix (SNGX), reported the acquisition of stock options on June 20, 2025. The insider was granted 17,647 stock options with an exercise price of $1.70 per share.

The options have a 10-year term expiring on June 20, 2035, and will vest in four equal installments on:

• September 20, 2025
• December 20, 2025
• March 20, 2026
• June 20, 2026

This equity-based compensation grant aligns the director's interests with shareholders through long-term stock ownership potential. The filing was reported within the required SEC timeline, demonstrating compliance with Section 16(a) reporting obligations.

Form 4 filing reveals that Robert J. Rubin, Director at Soligenix, received a stock option grant on June 20, 2025. The derivative securities transaction details include:

• Granted 17,647 stock options to purchase common stock
• Exercise price set at $1.70 per share
• Options expire on June 20, 2035
• Vesting schedule occurs in four equal installments: - September 20, 2025 - December 20, 2025 - March 20, 2026 - June 20, 2026

This equity compensation grant aligns the director's interests with shareholders through a standard 10-year term and quarterly vesting schedule over one year. The transaction was reported in compliance with SEC Section 16 requirements for insider trading disclosure.

Form 4 filing reveals that Diane L. Parks, Director at Soligenix, received a stock option grant on June 20, 2025. The derivative securities transaction details include:

• Granted 17,647 stock options to purchase common stock
• Exercise price set at $1.70 per share
• Options expire on June 20, 2035
• Vesting schedule occurs in four equal installments: - September 20, 2025 - December 20, 2025 - March 20, 2026 - June 20, 2026

This stock option grant represents standard director compensation and aligns the director's interests with shareholders through long-term equity incentives. The 10-year exercise period provides significant time value for these options.

Soligenix has filed a Form S-8 to register securities under its 2025 Equity Incentive Plan. The company, headquartered in Princeton, New Jersey, is classified as both a non-accelerated filer and a smaller reporting company.

Key filing incorporations include:

• Annual Report on Form 10-K for FY2024 (filed March 21, 2025)
• Q1 2025 Form 10-Q (filed May 9, 2025)
• Recent Form 8-K filings from February, March, and June 2025

The registration includes comprehensive indemnification provisions for directors and officers under Delaware law, including protection against personal liability for fiduciary duty breaches, except in cases of:

• Breach of duty of loyalty
• Acts not in good faith or involving intentional misconduct
• Unlawful dividend payments or stock repurchases
• Improper personal benefit transactions

On June 20, 2025, Soligenix, Inc. (Nasdaq: SNGX) filed an 8-K summarizing the results of its 2025 Annual Meeting of Stockholders.

• 2025 Equity Incentive Plan: Approved with 215,332 votes For, 91,937 Against and 57,226 Abstain (1,168,832 broker non-votes). Forms of stock option and restricted stock agreements were filed as Exhibits 10.2 and 10.3.
• Board Elections: All five incumbent directors were re-elected. Support ranged from 329,054 to 332,492 votes For; broker non-votes totaled 1,168,832.
• Say-on-Pay: Executive compensation received advisory approval (303,633 For; 53,830 Against; 7,032 Abstain).
• Auditor Ratification: Cherry Bekaert, LLP was ratified for FY 2025 (1,476,465 For; 54,474 Against; 2,388 Abstain).
• Adjournment Authority: Approved with 1,227,450 For; 295,013 Against; 10,864 Abstain.

No operational updates, financial results or major strategic transactions were disclosed; the filing is primarily governance-oriented and does not materially affect near-term fundamentals.